Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

AARP On Medicare Trustees Report: "Medicare's Accelerating Insolvency. Will Only Be Fixed By Comprehensive Reform In 2009."
AARP Executive Vice President John Rother issued the

Obama Names Alabama Family Physician Benjamin To Be Surgeon General
President Obama on Monday nominated Alabama family physician Regina Benjamin, founder of the Bayou La Batre Rural Health Clinic, to be the U.S. surgeon general, the AP/Detroit Free Press reports (Neergaard, AP/Detroit Free Press, 7/13). Benjamin"s clinic serves a low-income community of about 2,500 and has earned a national reputation treating all patients, regardless of their ability to pay. Benjamin founded the clinic in 1990 and repeatedly rebuilt it after two hurricanes and a fire (Zhang, Wall Street Journal, 7/14). In 2008, she received one of the MacArthur Foundation"s $500,000 "genius grants" (Lloyd, USA Today, 7/14). In 1995, Benjamin became the first black woman to be elected to the American Medical Association Board of Trustees. Benjamin also has served as associate dean for rural health at the University of South Alabama College of Medicine (Bellantoni, Washington Times, 7/13). In 2002, she became president of the Medical Association of the State of Alabama, making her the first black woman to be president of a state medical society (Mostrous/Shear, Washington Post, 7/14).Benjamin is a "devout Roman Catholic," according to the New York Times. The administration did not disclose her views on abortion. Benjamin routinely prescribes oral contraceptives, but the clinic does not have the facilities to perform abortions, according to nurse Audrey Bosarge, a colleague of Benjamin"s (Harris, New York Times, 7/14). In his announcement, Obama said Benjamin understands the needs of the low-income and uninsured U.S. residents, which makes her uniquely qualified to serve as surgeon general during health care overhaul negotiations (Wall Street Journal, 7/14). In accepting the nomination, Benjamin vowed to ensure that "no one falls through the cracks as we improve our health care system." Benjamin"s nomination requires Senate confirmation (AP/Detroit Free Press, 7/13).
News of the day
New Culprit Behind Obesity's Ill Metabolic Consequences
Obesity very often leads to insulin resistance, and now researchers reporting in the July 8 issue of Cell Metabolism, a Cell Press publication, have uncovered another factor behind that ill consequence. The newly discovered culprit - a protein known as pigment epithelium-derived factor (PEDF for short) - is secreted by fat cells. They also report evidence to suggest that specifically blocking that protein"s action may reverse some of the health complications that come with obesity.
Oncology

Nicotine's Double Role In Lung Cancer

A lung cancer treatment that inhibits nicotine receptors was shown to double survival time in mice, according to Italian researchers. The results of the early phase animal model study were reported in the June 15 issue of the American Journal of Respiratory and Critical Care Medicine. Changes in genes encoding nicotine receptors are strongly associated not only with the tendency to smoke, but with susceptibility to lung cancer. Nicotine exposure also heightens the expression of the nicotine receptors, which leads to increased cell proliferation and inhibition of apoptosis, further setting the stage for cancer. Patrizia Russo, Ph.D. and Laura Paleari, Ph.D. of the Lung Cancer Unit of the National Cancer Research Institute in Genoa, Italy and colleagues from San Raffaele Pisana Scientific Institute for Research, Hospitalization and Health Care (IRCCS), Catholic University, Campus Biomedico University in Rome, Mario Negri Institute in Milan and CEA Gyf sur Yvette in France showed in past research that an antagonist of nicotine acetylcholine receptors (nAChRs), may serve as an anticancer agent. The antagonist, called d-tubocurarine/í±-Cobratoxin (í±-CbT), specifically targeted the í±7 subunit of nAChRs, the area primarily associated with increased cell proliferation. In this study, the authors took the research a step further and showed that í±-CbT could inhibit non-small cell lung carcinoma (NSCLC) growth and prolong life in non-obese/severe combined immunodeficient (NOD/SCID) mice that had human NSCLC grafted to their lungs. This study attempted to mimic human cancer conditions more closely by delaying treatment until the tumors were well-established. In addition to control mice that were untreated, the researchers randomized one third of the mice to receive standard chemotherapy. They found that NOD/SCID mice treated with the standard chemotherapy agent, cisplatin, had a 16 percent longer median survival time than untreated mice (p= 0.05). Mice treated with í±-CbT, however, had an increased median survival time of 1.7-fold over the cisplatin-treated mice and 2.1-fold over the no-treatment controls (p=0.0005). "The results of this study show that í±-CbT, a powerful, high-affinity í±-7-nAChR inhibitor, induces antitumor activity against NSCLC by triggering apoptosis," wrote Dr. Russo. "The prolonged survival of í±-CbT-treated animals in our mouse model of NSCLC is most likely the result of several mechanisms, including various antiproliferative and antiangiogenic effects." The research also found that unaffected (i.e., noncancerous) cells showed no inhibition of proliferation when treated with í±-CbT, suggesting that the treatment would have limited if any toxic effects. Dr. Russo and colleagues postulated that this finding may be due to the reduced number of receptor binding sites on normal cells as opposed to cancerous cells. Conversely, they reported that cancer cells with the greatest number of receptor binding sites seemed to respond with the greatest sensitivity to the treatment. "The goal of this research line is to explore the widest range of possibilities of intervention on the΀  í±7-nAChRs. We hope to move further on towards the clinical setting experimentation phase for the assessment of potentially new treatment strategies for NSCLC," said Dr. Russo. An editorial in the same issue of the journal asked if nicotine may be to lung cancer what estrogen is to breast cancer. Eliot R. Spindel, M.D., Ph.D., of Oregon Health & Science University, stated that estrogen can stimulate the development of breast cancer and estrogen-receptor antagonists, such as tamoxifen, provide therapeutic benefit. In support of a carcinogenic role for estrogen, the incidence of breast cancer appears to be decreasing as estrogen hormone replacement therapy is being used less often. Likewise, nicotine may promote lung cancer yet nicotine receptor antagonists may offer treatment options for patients with lung cancer. John Heffner, M.D., past president of the ATS stated that "this research clearly has profound clinical implications regarding the role of nicotine in stimulating lung cancer and nicotine receptor antagonists in treating the disease. The highly addictive nature of nicotine, however, complicates patients" ability to quit smoking and avoid ongoing nicotine exposure." "This [addictive nature of nicotine] underscores the importance of potential FDA regulation of nicotine in tobacco products to limit exposure to this drug that promotes tumor growth," wrote Dr. Spindel. Keely Savoie American Thoracic Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009